195 related articles for article (PubMed ID: 34703426)
1. Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient.
Berbert Ferreira S; Berbert Ferreira R; Neves Neto AC; Assef SMC; Scheinberg M
Case Rep Dermatol; 2021; 13(1):190-194. PubMed ID: 34703426
[TBL] [Abstract][Full Text] [Related]
2. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Liu LY; Strassner JP; Refat MA; Harris JE; King BA
J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
[TBL] [Abstract][Full Text] [Related]
3. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Olamiju B; Craiglow BG
Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
[TBL] [Abstract][Full Text] [Related]
5. Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
Gianfaldoni S; Tchernev G; Wollina U; Roccia MG; Fioranelli M; Lotti J; Rovesti M; Satolli F; Valle Y; Goren A; Tirant M; Situm M; Kovacevic M; França K; Lotti T
Open Access Maced J Med Sci; 2018 Jan; 6(1):46-48. PubMed ID: 29483979
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Craiglow BG; King BA
JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
[TBL] [Abstract][Full Text] [Related]
7. Repigmentation of vitiligo-associated eyelash leukotrichia with topical tofacitinib.
Kim SR; Craiglow BG
JAAD Case Rep; 2021 Oct; 16():90-91. PubMed ID: 34541274
[No Abstract] [Full Text] [Related]
8. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
9. A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib.
Lin Q; Zhu J; Gao X
Clin Cosmet Investig Dermatol; 2024; 17():707-711. PubMed ID: 38524393
[TBL] [Abstract][Full Text] [Related]
10. Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report.
Satkunanathan S; Boshra M; Chang J; Bose R
SAGE Open Med Case Rep; 2024; 12():2050313X241231527. PubMed ID: 38362228
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
Utama A; Wijesinghe R; Thng S
Int J Dermatol; 2024 Apr; ():. PubMed ID: 38610078
[TBL] [Abstract][Full Text] [Related]
12. A review of JAK and IL-23 inhibitors to treat vitiligo.
Lee H; Cowan TL; Daniel BS; Murrell DF
Australas J Dermatol; 2023 May; 64(2):204-212. PubMed ID: 36810815
[TBL] [Abstract][Full Text] [Related]
13. Disorders of Hypopigmentation.
Dina Y; McKesey J; Pandya AG
J Drugs Dermatol; 2019 Mar; 18(3):s115-s116. PubMed ID: 30909355
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
Sardana K; Muddebihal A; Khurana A
Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
[TBL] [Abstract][Full Text] [Related]
15. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
[TBL] [Abstract][Full Text] [Related]
16. Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy.
Li X; Sun Y; Du J; Wang F; Ding X
Clin Cosmet Investig Dermatol; 2023; 16():635-638. PubMed ID: 36936753
[TBL] [Abstract][Full Text] [Related]
17. Biologic and targeted therapeutics in vitiligo.
Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
[TBL] [Abstract][Full Text] [Related]
18. A Literature Review Investigating the Use of Topical Janus Kinase Inhibitors for the Treatment of Vitiligo.
White C; Miller R
J Clin Aesthet Dermatol; 2022 Apr; 15(4):20-25. PubMed ID: 35465035
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
[TBL] [Abstract][Full Text] [Related]
20. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
